Skip to content

Analysis of risk factors for portal vein thrombosis after portosystemic devascularization in patients with cirrhotic portal hypertension and gastrointestinal bleeding

A prospective nested case-control study of neutrophil extracellular traps in portal vein thrombosis after portosystemic devascularization in patients with liver cirrhosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083109
Enrollment
Unknown
Registered
2024-04-16
Start date
2024-05-01
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhotic portal hypertension with gastrointestinal bleeding

Interventions

Thrombus group :None
Control group (No thrombosis):None

Sponsors

The Second Hospital of Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients with EGVB secondary to cirrhotic portal hypertension have a Child-Pugh score of A or B for liver function; (2) previous history of EGVB, and after conservative treatment (including treatment such as vascular interventional embolization, endoscopic variceal ligation and injection sclerotherapy, compression hemostasis treatment of three - cavity two - capsule tube and medication), there is still a history of gastrointestinal bleeding; (3) preoperative abdominal CT or ultrasound examination of the portal vein and its branches showed no thrombosis; (4)no liver cancer or other malignant tumors found; (5) No history of using anticoagulants before surgery; (6) adult patients who agreed to and underwent splenectomy and oesophagogastric devascularization and signed an informed consent form; (7) After evaluation, organs such as the heart, lungs, and kidneys are able to tolerate surgery and there are no obvious surgical contraindications.

Exclusion criteria

Exclusion criteria: (1) Severe dysfunction of important organs such as the heart, lungs, and kidneys that cannot tolerate surgery; (2) Individuals with severe coagulation disorders; (3) Patients with malignant tumors or other hematological diseases; (4) Accompanied by severe infections; (5) Patients with gastrointestinal bleeding without cirrhosis; (6) Patients who are unable to complete the experiment or have difficulty following medical advice.

Design outcomes

Primary

MeasureTime frame
Portal vein thrombosis, blood flow velocity;

Secondary

MeasureTime frame
Liver function, operation time, blood loss, length of hospital stay, etc.;

Countries

China

Contacts

Public ContactXiaohu Guo

The Second Hospital of Lanzhou University

guoxiaohu2011@126.com+86 931 519 0524

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026